Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment

NCT02506686 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2015-07-23

No results posted yet for this study

Summary

A prospective, open-label study investigated the pharmacokinetic profile of meropenem in patients with post-neurosurgical central nervous system (CNS) infection, especially its BBB penetration into cerebrospinal fluid (CSF).

Conditions

  • Central Nervous System Infections

Interventions

DRUG

Meropenem

Meropenem i.v.

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Jufang Wu, MD · Huashan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02506686 on ClinicalTrials.gov